drugset / Trial / NCT02248922

Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa

NCT02248922

Phase 4 Terminated 17 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study was to evaluate lung clearance index (LCI) by a standardized procedure in a well characterized study setting and to assess feasibility of LCI as a more sensitive method than forced expiratory volume at 1 second (FEV1) to measure effectiveness of antibiotic therapy in patients with CF aged 6 years and older with mild to moderate lung disease.

Timeline

Start
2015-01-27
Primary completion
2017-04-10
Completion
2017-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 300 mg Inhaled